| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B40-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2008-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6eca7385604e13eb6870499a13d8f0c9 |
| publicationDate |
2010-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010092485-A1 |
| titleOfInvention |
Genetic Markers for Predicting Responsiveness to Combination Therapy |
| abstract |
The invention provides compositions and methods for determining the likelihood of successful treatment with an effective amount of an anti-VEGF antibody or equivalent thereof, in combination with anti-EGFR antibody or equivalent thereof, and, in some aspects in combination with a topoisomerase inhibitor. The methods comprise determining the identity of a gene of interest in a patient sample and correlating the patient's genotype with the predictive response. Patients identified as responsive are then treated with the appropriate therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013089496-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015157655-A3 |
| priorityDate |
2007-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |